Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Neuroendocrine Tumors 4Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Appendiceal Neoplasms 1

Interventions

Mitomycin 6Leucovorin 4Fluorouracil 4Oxaliplatin 3dehydroftorafur 2Mitozytrex 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Doxorubicin 2Cisplatin 2Biopsy 2surufatinib 1sodium thiosulfate 1sintilimab 1nilotinib 1irinotecan sucrosofate 1Surveys and Questionnaires 1Specimen Handling 1Platinum 1Pafolacianine 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immunoglobulin G 1Floxuridine 1Electrocardiography 1Disulfides 1Cytoreduction Surgical Procedures 1Cryotherapy 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Appendiceal Neoplasms × surufatinib × 1 year × Clear all
NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
36 enrolled
Gastrointestinal

Appendiceal Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡